Exclusive Summary

• - Patents: Core patents expired in 2011–2012 with broad generic entry, leaving minimal global IP barriers.
• - Registration: EU27 approvals in place provide strong quality credentials and enable rapid distribution and re-registration.
• - Formulation: Pediatric-friendly oral suspension (common doses 2.5 mg/5 mg), once-daily and low-sedation, suitable for children and adults.
• - Demand: Allergic rhinitis affects ~500 million people and chronic urticaria 0.5–1% of the population, driving steady year-round and seasonal use.
• - Pricing: Typical 50–80% discount vs originator supports competitiveness in public tenders and private-pay markets.